Irving Lab members

unil web full screen image 1200x300 (5).png

Sarah ASH
Oncology Lausanne Irving Group Sarah Ash_2023.png Postdoctoral researcher
CONTACT ME

Research interest

I have a long-standing passion for oncology research, with a particular interest for immuno-oncology. In my postdoctoral role, I will focus on bioengineering strategies to improve CAR T-cell homing, persistence, and safety in the context of solid tumors.

Background

I completed my Bachelor’s in Biomedical Sciences at the University of Leeds (UK) during which I undertook a one-year industrial placement at AstraZeneca working on high-throughput oncology co-culture models for drug screening. Following this, I went on to complete my PhD at the Institute of Cancer Research (London, UK), where my research focused on targeting the solid tumor microenvironment with CAR T-cells. As a postdoctoral researcher under the supervision of Dr Melita Irving, part of the Hi-TIDe, I continue to work on strategies to improve CAR T-cell targeting of solid tumors.

Greta GIORDANO ATTIANESE
Irving Lab GretaGiordanoA-crop3836x4227.jpg Research associate
CONTACT ME

Research interest

My research interests are in the development of function and safety enhanced ON/OFF-switch CARs as well as the optimization of gene-engineering strategies such as by CRISPR-Cas9 for the clinical translation of tumor-directed T-cell products.

Background

I did my Master’s in Medical Biotechnology in Milan before undertaking a one-year internship at Texas Children’s hospital to learn about CAR-T cell technologies. On returning to Italy, I pursued a PhD in Immunology. I undertook my postdoctoral studies in Switzerland, in genomics and epigenetics, after which I took up my position as Research associate within the Hi-TIDe.

Morteza HAFEZI
Irving Lab Mortez Hafezi-crop532x530.png PhD student
CONTACT ME

Research interest

In our group, we pursue innovative ways to improve TCR T cell therapy for clinical application. As a PhD student in the Hi-TIDe, my focus will be on improving the safety and efficacy of currently available therapeutic TCR T cell therapy.  

Background

During my studies in Singapore, I became very interested in translational immunology. I pursued my passion for working in T cell immunotherapy at Duke-NUS medical school. During my research at Duke, I worked on developing a new generation of Armored TCR T cells for treating liver transplant patients with recurrent cancer.

Paraskevas KOSTI
Irving Lab_Kosti_P.jpg

Post doc
CONTACT ME

Research interest

My research interests center on tumor immunology and synthetic biology strategies to harness the immune system to fight cancer. I am currently working on developing new gene-engineering strategies to enhance T cell immunotherapies for solid cancers. 

Background 

I have been working in the field of CAR T cell immunotherapy since 2014 when I first joined the CAR T cell team at the University College London Cancer Institute, as part of my MSc at UCL. I undertook my PhD at King’s College London developing and validating a novel CAR T cell immunotherapy approach to specifically activate CAR T cells within the TME­­—an approach that can potentially open CAR T cell therapy to previously difficult-to-target solid tumors.  I have been involved in various academia and industry CAR/TCR projects and I am fascinated to see the potential of these living immunotherapies to be used to efficiently treat cancer patients.

Laetitia PERICOU
Irving Lab L Pericou-resize300x316.jpg Technician
CONTACT ME

Research interest

I am interested in the development of targeted therapies for neurodegenerative diseases and cancer.

Background

My background is the fields of molecular and cellular biology, biochemistry, immunology and animal experimentation. I completed my thesis in the Alzheimer and tauopathies group at the Lille Neuroscience and Cognition Research Centre in France. I subsequently worked in the Neuropathy and neuromodulation laboratory of Pr Nicole Déglon at the CHUV and the group of Dr Olivier Dormond in the Department of visceral Surgery. I joined the Hi-TIDe in 2021.

Patrick REICHENBACH
light-blue-man-silhouette-th.png

Technician
CONTACT ME

 

Bili SEIJO
Irving Lab Bili Seijo.jpg Technician
CONTACT ME

Research interest

I am interested in the design of DNA constructs for in vitro/in vivo experiments as well as in the production of recombinant proteins (cytokines, decoys, mutants).

Background

My background is in molecular biology, biochemistry, structural biology. I gained my University Diploma in Technology in Bioengineering from the Université de Créteil (France) in 1998 and worked at the CNRS before joining the Hi-TIDe at the University of Lausanne in 2016.

Melanie TRIBOULET
Irving Group Melanie Triboulet-crop356x359.jpg

Technician
CONTACT ME

Research interest

I joined the Hi-TIDe in 2021 to work on the development of engineered T cells for cancer immunotherapy.

Background

After completing my Master’s degree in Biological Engineering at the Polytech Clermont-Ferrand (France) in 2015, I joined Pr Jeffrey’s lab at Stanford University as a Research assistant. While at Stanford, I was involved in a collaboration with a start-up company called Vortex Biosciences and worked on validating Vortex CTC isolation technology. Subsequently, from 2017 to 2021, I was employed as a Research engineer and Scientific writer in the field of preclinical studies in immuno-oncology at Transcure Bioservices in France.

TOP ^

Romain VUILLEFROY DE SILLY
Irving Lab Romain Vuillefroy de Silly-crop2096x2184.jpg Postdoctoral researcher
CONTACT ME

Research interest

I am interested in the study of fundamental immunology (especially immune cell physiology) and molecular biology, and to challenge (old) dogmas/paradigms. My research focus includes the exploration of basic chemical/physical properties (e.g. oxygen tensions, pH, redox), cell signalling, metabolism, and gene-engineering approaches linked to optimise immune responses.

Background

I completed my PhD, exploring how cysteine metabolism impacts immune response to transplantation, in 2011 at INSERM (France). I started a postdoc in 2012 at the University of Geneva to decipher how low oxygen fractions found in the tumor microenvironment impacts the anti-tumor CD8+ T-cell response. I joined the Hi-TIDe in 2016 with the aim of delineating how low pH/acidity disturbs the anti-tumor CD8+ T-cell response: the ultimate goal is to improve cancer immunotherapy efficacy by rendering CD8+ T cells resistant to acidity via gene engineering.

TOP ^

images (c) unsplash/ian schneider-tam/helena lopes

Follow us:  

CONTACT

Lausanne Oncology Irving Lab.png

Melita IRVING
Group leader
Human integrated tumor immunology discovery engine (Hi-TIDe)

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Ludwig Lausanne RGB-crop461x374.jpg (Print)

Phone +41 21 692 59 61
Fax +41 21 692 59 95
E-mail

TOP ^

The Irving Lab is based at:

Biopôle
Ch. des Boveresses 155
CH-1066 Epalinges
Switzerland

m9JS5ORM-resize158x246.jpg

Ch. des Boveresses 155 - CH-1066 Epalinges
Switzerland
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
Ludwig Cancer ResearchUniversité de LausanneCentre Hospitalier Universitaire Vaudois (CHUV)